NCT00379431View on ClinicalTrials.gov

A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 27, 2006

Primary Completion Date

February 2, 2009

Study Completion Date

February 2, 2009

Conditions
Early and Severe Systemic Sclerosis
Interventions
DRUG

Administration of rituximab and methylprednisolone

"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."

Trial Locations (4)

9000

University Hospital Ghent, Ghent

Unknown

UCL St. Luc Brussel, Brussels

UZ Brussel, Brussels

UZ Gasthuisberg Leuven, Leuven

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT00379431 - A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab | Biotech Hunter | Biotech Hunter